Health & Fitness
Mon, November 28, 2011
PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will be presenting at the Piper Jaffray 23rd Annual Healthcare Conference at 2:00 p.m. EST on November 29, 2011. The conference is being held November 29-30, 2011 at the Palace Hotel in New York City.
Piper Jaffray is using an aunpluggeda fireside chat format for the presentation sessions. Edward J. Quilty, Derma Sciencesa President and Chief Executive Officer, will provide a brief overview of the Companyas business strategy, after which a Piper Jaffray equity analyst will moderate a question and answer session.
There will be a corresponding audio webcast of the presentation, which can be accessed by visiting: [ http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=DSCI&item_id=4676157 ].
The presentation will be archived shortly after the live event and available for 90 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Derma Sciencesa website at [ www.dermasciences.com ].
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. Its MEDIHONEY product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB for better management of wound exudate, and BIOGUARD for infection prevention.
For more information please visit [ www.dermasciences.com ].
